期刊
BIOCHEMICAL PHARMACOLOGY
卷 127, 期 -, 页码 1-12出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bcp.2016.09.014
关键词
Respiratory syncytial virus; Antivirals; Model systems; Fusion inhibitors; Polymerase inhibitors
资金
- Wellcome Trust [WT-106327]
The development of antiviral strategies to prevent or treat respiratory syncytial virus (RSV) infections is of great importance, especially considering the fact that RSV is one of the most important causes of pediatric respiratory infections. However, despite intense efforts, there is no antiviral or vaccine approved for the prevention or treatment of RSV infections. Several inhibitors, targeting different RSV proteins have been discovered over the past decade. We here review the most important chemical series as well as recent developments in understanding which viral proteins and/or host cell factors are good targets for inhibition of viral replication. In addition, we highlight the current in vitro and in vivo model systems of the disease. A number of molecules are currently in (advanced) preclinical or clinical development. Significant breakthroughs in the field may be expected in the upcoming years. (C) 2016 The Authors. Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据